People · Operator

John N. Allport

Named in public records as an officer, director or promoter · active 2011–2011 · Pharmaceuticals

1
Companies
1
Filings
$17.5M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Intellipharmaceutics International Inc.PharmaceuticalsSeries A$17.5M$31.4M2011
Operator network

John N. Allport at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Eldon R. Smith · 3 companies · 1 sharedEldon R. SmithEldon Smith · 2 companies · 1 sharedEldon SmithAmina Odidi · 1 companies · 1 sharedAmina OdidiAndrew Patient · 1 companies · 1 sharedAndrew PatientAndrew R. Patient · 1 companies · 1 sharedAndrew R. PatientBahadur Madhani · 1 companies · 1 sharedBahadur MadhaniBahadur R. Madhani · 1 companies · 1 sharedBahadur R. MadhaniIsa Odidi · 1 companies · 1 sharedIsa OdidiKenneth Keirstead · 1 companies · 1 sharedKenneth KeirsteadKenneth R. Keirstead · 1 companies · 1 sharedKenneth R. Keirst…Michael R. Campbell · 1 companies · 1 sharedMichael R. Campbe…Patrick N. Yat · 1 companies · 1 sharedPatrick N. YatShameze N. Rampertab · 1 companies · 1 sharedShameze N. Ramper…Intellipharmaceutics International Inc. · $17.5M raisedIntellipharmaceutics …John N. AllportJA
John N. Allport Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside John N. Allport on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Eldon R. Smith13
Eldon Smith12
Shameze N. Rampertab11
Amina Odidi11
Isa Odidi11
Kenneth R. Keirstead11
Kenneth Keirstead11
Andrew Patient11
Bahadur Madhani11
Michael R. Campbell11
Patrick N. Yat11
Andrew R. Patient11
Bahadur R. Madhani11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.